Immunotherapies for hepatocellular carcinoma
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
Evolving therapeutic landscape of advanced hepatocellular carcinoma
C Yang, H Zhang, L Zhang, AX Zhu… - Nature reviews …, 2023 - nature.com
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
Targeting tumor-associated macrophages to synergize tumor immunotherapy
X **ang, J Wang, D Lu, X Xu - Signal transduction and targeted therapy, 2021 - nature.com
The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …
immunotherapies have raised hope for a successful control of these advanced diseases, but …
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Immune-based therapies such as immune checkpoint inhibitors have revolutionized the
systemic treatment of various cancer types. The therapeutic application of monoclonal …
systemic treatment of various cancer types. The therapeutic application of monoclonal …
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
B Sangro, C Gomez-Martin, M de la Mata… - Journal of …, 2013 - Elsevier
BACKGROUND & AIMS: Tremelimumab is a monoclonal antibody that blocks cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4), an inhibitory co-receptor that interferes with T …
lymphocyte-associated antigen 4 (CTLA-4), an inhibitory co-receptor that interferes with T …
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
Y Fu, S Liu, S Zeng, H Shen - Journal of Experimental & Clinical Cancer …, 2019 - Springer
Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …
indicate that the global health burden of this disease will continue to grow. Most patients with …
Immunological landscape and immunotherapy of hepatocellular carcinoma
J Prieto, I Melero, B Sangro - Nature reviews Gastroenterology & …, 2015 - nature.com
Advanced hepatocellular carcinoma (HCC) is a serious therapeutic challenge and targeted
therapies only provide a modest benefit in terms of overall survival. Novel approaches are …
therapies only provide a modest benefit in terms of overall survival. Novel approaches are …
Cancer vaccine therapeutics: limitations and effectiveness—A literature review
M Kaczmarek, J Poznańska, F Fechner, N Michalska… - Cells, 2023 - mdpi.com
In recent years, there has been a surge of interest in tumor microenvironment-associated
cancer vaccine therapies. These innovative treatments aim to activate and enhance the …
cancer vaccine therapies. These innovative treatments aim to activate and enhance the …